Well, maybe not as good as I originally thought. ALK plus EGFR is 6% of ALK+ population not 6% of NSCLC as I originally calculated (thanks for the heads-up, Peter).
In my original post, I thought i was being conservative by assuming ALK+ plus ALK/EGFR in total was 6% of NSCLC, or 11,500 patients in US, but in actuality the number is around 8,600 which would make it closer to a billion dollar market in the US before factoring in rest of world, ROS1, increase in patients from improved survival rates, and EGFR opportunity.
News 
Market Data 
Discover 
